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Background: Celiac disease (CD) is a global health problem and its prevalence is underestimated, especially in
Latin American populations. Our aim was to evaluate the clinical features, psychological factors, and health-related
quality of life (QoL), before and after diagnosis, in a representative sample of adult Mexican Mestizo patients
presenting with CD.
Methods: A cross-sectional analysis was conducted on patients seen at two tertiary referral centers in Mexico. QoL
before and after CD diagnosis was evaluated using the EuroQoL 5D, the Hospital Anxiety and Depression Scale
(HADS), and the disease-specific Celiac Symptom Index (CSI) questionnaires.
Results: We included 80 patients (80% were women, with a mean age of 48.6 ± 14.1 years). The most common
symptoms were diarrhea (86%), bloating (77.5%), and abdominal pain (71.3%). Mean symptom duration was
10.33 ± 6.3 years. Fifty-one patients (63.8%) had a previous diagnosis of irritable bowel syndrome (IBS) and 23
(28.8%) had one of functional dyspepsia. Questionnaire respondents rated their health status at 50% before
diagnosis (0 = worst imaginable state, 100 = best imaginable state) and there was a significant improvement of 26%
after diagnosis. Thirty-nine percent of the patients had a CSI score > 45 and they were the ones that had been
previously diagnosed most often with IBS (p = 0.13) or dyspepsia (p = .036).
Conclusions: At the time of diagnosis, Mexican Mestizo patients with CD had poor QoL. Long-standing symptoms
and a previous diagnosis of functional disorders were associated with worse QoL. As in other populations, our
results support the need for a detailed examination of cost-effective strategies for increasing CD awareness in
clinical practice.
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Celiac disease (CD) is a chronic, immune-mediated en-
teropathy of the small intestine precipitated by exposure
to dietary gluten in genetically predisposed individuals
[1,2]. Its typical clinical presentation is characterized by
signs or symptoms of malabsorption (anemia, abdominal
pain, chronic diarrhea, or malnutrition) as a consequence
of chronic inflammation and villous atrophy of the small
bowel mucosa [1,2]. However, this clinical picture has
changed over time and, at present, a considerable number
of patients do not have gastrointestinal symptoms, but* Correspondence: joremes@uv.mx
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article, unless otherwise stated.instead, present with atypical symptoms or no symptoms
at all. Because of this heterogeneous clinical picture, a
large proportion of patients remain unrecognized. Prompt
diagnosis is required in order to prevent chronic compli-
cations such as osteoporosis, anemia, malnutrition, and in
some cases, malignancies such as intestinal lymphomas.
In addition, the symptoms of undiagnosed celiac disease
are associated with a prolonged and substantial decrease
in quality of life (QoL) that can be similar to or worse
than that of subjects with irritable bowel disease (IBS),
when compared with healthy controls [3,4]. Previous
studies have associated a reduced quality of life in CD
patients with abdominal pain, bloating, psychological
distress, anxiety, and depression [5-7].ed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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lifelong elimination of gluten (gluten-free diet or GFD)
results in significant clinical improvement in most pa-
tients. However, even though the majority of patients do
quite well with a GFD treatment is burdensome in terms
of increased cost [8], reduced nutritional value [9], and
social constraints [6,10-12].
Recent studies have shown that CD is a global health
problem and prevalence is estimated at between 1:250
and 1:67 in some populations [13,14]. Actual prevalence
may be underestimated in some areas, such as Latin
America or in Hispanic populations [1]. It has recently
been reported that seroprevalence for CD using both
anti-transglutaminase (tTg-IgA) and anti-endomysial an-
tibodies (EMA) is 0.59% (0.27%-1.29%) in the Mexican
Mestizo population [15]. Furthermore, two recent stud-
ies have characterized the genetic profile of CD in
Mexico [16,17]. Sotelo et al. found HLA DQ2/DQ8 hap-
lotypes in 11 out of 15 children with CD in Northern
Mexico [16] and Cerda et al. found a more frequent ex-
pression of DQ8 haplotypes in adults with CD [17].
Thus, prevalence and genetic susceptibility in Mexican
Mestizo CD subjects is similar to that observed by
others, including that of the general U.S. population
[1]. However, there is a lack of information related to
the characteristics and factors that may have an impact
on QoL in Hispanic patients with CD. Our aim was to
evaluate the clinical features, psychological factors, and
health-related QoL, before and after diagnosis, in a rep-
resentative sample of adult Mexican Mestizo patients
with CD.
Methods
Between January and August of 2011, patients with CD
were recruited at two different tertiary referral centers:
1) consecutive CD patients seen at the Instituto Nacional
de Ciencias Médicas y Nutrición Salvador Zubirán, and 2)
consecutive patients attended to at the Instituto de Inves-
tigaciones Medico Biologicas, Universidad Veracruzana,
Veracruz, Mexico. CD diagnosis was established based on
the following criteria: 1) compatible clinical characteris-
tics, 2) positive EMA and/or tTg IgA antibodies, and 3)
suggestive histological features according to the Marsh
Classification.
The Mexican Mestizo is a complex mixture of European
(Caucasian) and Native American (Mongoloid) genetics,
constituting the core of Mexican and Latin American
populations [18]. The Mexican Mestizos in this study were
defined as individuals that came from two generations,
including their own, of persons born in Mexico, de-
scendants of the original autochthonous inhabitants of
the region, as well as of white, mainly Spanish, or black
African individuals that came to America in the 16th
century [18].A cross-sectional analysis was carried out using a spe-
cific, multiple choice questionnaire for collecting the in-
formation in relation to demographics, family history,
symptoms experienced before CD diagnosis (diarrhea,
bloating, abdominal pain, fatigue, early satiety and/or
postprandial fullness [dyspeptic symptoms], weight loss,
constipation, headache, skin rashes) and their duration,
a prior diagnosis of anemia, osteoporosis, infertility, or
recurrent abortion, as well as alternative diagnoses made
by attending physicians, especially IBS or dyspepsia, and
the number of symptom-related consultations. QoL was
evaluated through the EuroQoL 5D (EQ-5D validated
Spanish version) [19]. At the time of the study, all the
patients had been on a GRD for at least 6 months. The
EQ-5D includes both a descriptive system comprised of
five health-related domains (mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression) divided
into three levels of severity (no problems, some problems,
severe problems) and a visual analogue scale (VAS) for
recording overall health [19]. Patients answered both
the descriptive questions and the VAS in relation to
two distinct moments in time: “before” and “after” the
definitive diagnosis of CD.
The Celiac Symptom Index (CSI), a disease-specific
questionnaire [20], was also part of the evaluation. It al-
lows for disease-specific monitoring of symptoms as an
independent outcome measure or as part of a surrogate
for disease activity in individuals with CD. It is made
up of sixteen items, 11 of which evaluate “specific symp-
toms” and 5 evaluate “general health”. Each question is
answered on a Likert scale from 1 to 5. Overall symptom
scores were calculated through simple addition, with
higher scores denoting more severe symptoms. Accord-
ing to previous studies, scores of 45 or higher are asso-
ciated with a relatively poor quality of life and worse
GFD adherence [20]. Therefore, we analyzed subjects
with a CSI > 45.
The Hospital Anxiety and Depression Scale (HADS)
was also applied. This scale has been used in Mexico
with drug abusers, burn patients, renal insufficiency pa-
tients, and obese subjects [18]. According to previous
studies, 8 is the best cut-off point for anxiety and 7 for
depression. We instructed the patients to answer the
HADS questionnaire in relation to their symptoms be-
fore CD diagnosis.
The Ethics Committee and the Institutional Review
Board at the “Instituto de Investigaciones Médico Bioló-
gicas”, Universidad Veracruzana, Mexico, approved the
study. All participants signed statements of informed
consent as voluntary participants in the study.
Statistical analysis
The categorical variables were presented as absolute and
relative frequencies, whereas the continuous variables
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was reported using relative frequencies with the corre-
sponding 95% confidence intervals (based on the binomial
distribution). The Student’s t test and Mann–Whitney U
test were used for evaluating the continuous data; the chi-
square and Fisher exact tests were used for the categorical
data. Statistical significance was set at a p <0.05. Correla-
tions between the EQ-D5, VAS, and HADS were calcu-
lated with the Spearman’s rho. Data were analyzed using
the SPSS software (SPSS 10, Chicago, IL and NCSS-200,
Kaysville, UT).
Results
One hundred and eight subjects were invited to partici-
pate in the study, but complete information was pro-
vided by 80 subjects (74%). Sixty-four of the respondents
were women (80%) and 16 were men (20%), with a mean
age of 48.6 ± 14.1 years (range: 23–75 years). The most
common symptoms were diarrhea (86%), bloating (77.5%),
abdominal pain (71.3%), fatigue (67.5%), dyspeptic symp-
toms (65%), weight loss (62.5%), constipation (37.5%),
headache (36.3%), skin rashes (33.8%), aphthous ulcers
(30%), chronic anemia (26.3%), osteoporosis (17.5%), infer-
tility (10%), and recurrent abortion (10%). Seven subjects
(9.09%) had a family history of CD (Table 1).Table 1 Characteristics of CD subjects




Age (years, mean, SD) 48.6 ± 14.1
Duration of symptoms prior to diagnosis (years, mean, SD) 10.33 ± 6.3
Diarrhea 69 (86%)
Bloating 62 (77.5%)
Abdominal pain 57 (71%)
Fatigue 54 (67.5%)
Dyspeptic symptoms 52 (65%)
Weight loss 50 (62.5%)
Constipation 30 (37.5%)
Headache 29 (36.3%)
Skin rashes 27 (33.8%)




Recurrent abortion 8 (10%)
Family history of CD (n,%) 7 (9%)
Previous diagnosis of IBS 23 (29%)
CD = celiac disease, IBS = irritable bowel syndrome, SD = standard deviation.Mean symptom duration before diagnosis was 10.33 ±
6.3 years (range: 1–16 years). On average, patients con-
sulted 6.6 physicians prior to correct diagnosis. Correct
diagnosis was made by a gastroenterologist in 56 cases,
an internist in 10 cases, a nutritionist in 10 cases, and a
dermatologist in 4 cases. Ninety percent of the patients
(n = 72) stated that information regarding the disease
was limited in Mexico and 73% (n = 58) are currently
consulting a dietician.
Fifty-one patients (63.8%) had a previous diagnosis of
IBS and 23 (28.8%) of functional dyspepsia. The CD sub-
jects with an initial IBS diagnosis were older (43.3 vs.
28.9 years, p = 0.004), went to more consultations (8 vs.
4 visits per year, p = 0.05), and had a longer period of
time with symptoms (10.5 vs. 7.25 years, p = 0.06) than
those without that initial diagnosis.
The EQ-5D respondents’ self-reported health status, be-
fore and after celiac disease diagnosis, is shown in Table 2.
After CD diagnosis, the patients reported a mean im-
provement in overall health status of 26 points through
the VAS (50 vs. 76) (Figure 1).
At the time of the evaluation, 20 patients had a CSI
score > 45 (15 women); they were the subjects that had an
initial diagnosis of IBS (p = 0.13) or dyspepsia (p = .036),
had symptoms for a long period of time (p = 0.04), had
more medical consultations (p = 0.024), and displayedTable 2 EQ-5D respondents’ self-reported health status
before diagnosis of celiac disease (retrospective) and
at the present time: number and percentage by
response level









Before diagnosis 54 68 23 29 2 3
At present 69 86* 11 14 0 0
Self-care
Before diagnosis 72 90 7 9 1 2
At present 77 96* 3 4 0 0
Usual activities
Before diagnosis 50 62 23 29 7 9
At present 67 84* 11 14 1 2
Pain
Before diagnosis 14 18 42 52 24 30
At present 45 56* 30 37 5 7
Anxiety/depression
Before diagnosis 35 44 31 39 14 17
At present 54 68* 23 30 2 3
*Proportion reporting no problem significantly different at present compared
with before diagnosis (McNemar-Bowker Chi-square test, p <0.01).
Figure 1 Visual analogue scale scores before and after celiac disease diagnosis (0 = worst imaginable state, 100 = best imaginable state).
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(Table 3).
According to the HADS, 65% (n = 52) presented with
anxiety and 60% (n = 48) with depression. There was a
negative correlation between QoL (using the VAS, post-
diagnosis) and anxiety and depression (r = −0.59 and
r = −0.62) (Figure 2).
Discussion
Although CD was traditionally considered a frequent
disease in North America and Europe, recent prevalence
studies have indicated that it could be a common health
problem worldwide [13,14,19]. To the best of our know-
ledge, our study is the first characterization of the clin-
ical features, psychological factors, and QoL in adult
Mexican Mestizos with CD. In the past, CD was consid-
ered an uncommon disease in Mexico, but recent stud-
ies have shown that its prevalence in Mexico is at least
similar to that of some non-Hispanic countries [1,15].
Like other CD populations, most of our patients had
typical symptoms (diarrhea, bloating, abdominal pain,fatigue, dyspeptic symptoms, and weight loss). How-
ever, up to 30% had atypical manifestations, such as
constipation and dermatologic manifestations. Interest-
ingly, as reported in other countries, Mexican patients
with CD may also suffer from other extraintestinal ma-
nifestations, such as osteoporosis, infertility, or recur-
rent abortion [1,2,20]. Thus, even in Mexico, atypical
CD is increasing, most likely related to the widespread
use of serologic testing and disease awareness in special
populations.
As is the case in other ethnic groups, most of our pa-
tients are middle-aged women whose diagnosis has been
considerably delayed [20]. Our study found a mean symp-
tom duration before diagnosis of 10.32 years; this time
lapse is similar to that reported by Green et al. in a large
American study [4] and by Gray et al. in a recent British
cohort [7]. This delay in CD diagnosis could possibly be
explained by the limited availability of serologic tests or by
myths and misconceptions regarding CD. For instance,
some common CD myths in Mexico are: “The Hispanic
population is protected against CD by its dietary staples”
Table 3 Factors associated with a celiac score Index
higher than 45
Variable CSI > 45 CSI < 45 p value
n = 20 n = 60
Sex
Men (n,%) 5 (25) 11 (19) 0.23
Women (n,%) 15 (75) 49 (81)
Age
Mean (SD, years) 43.2 ± 12 40.9 ± 17 0.56
Duration of symptoms prior
to diagnosis
Mean (SD, years) 11.8 ± 4 6.8 ± 5.6 0.0001
Previous IBS diagnosis
Yes (n,%) 17 (85) 34 (57) 0.04
No (n,%) 3 (15) 26 (43)
Previous dyspepsia diagnosis
Yes (n,%) 14 (70) 9 (15) <0.0001
No (n,%) 6 (30) 51 (85)
Pain
At time of survey 11 (55) 22 (36) 0.23
Anxiety or depression
At time of survey 14 (70) 18 (30) 0.003
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is no known genetic susceptibility related to HLA genes in
Hispanics”. In addition, the high rate of misdiagnoses is
due to a lack of knowledge among healthcare workers
about the disease.Figure 2 A significant negative correlation between QoL (using the E
(r = −0.59 and r = −0.62) was found.Once they are referred to a gastroenterologist, a sub-
stantial number of patients complaining of symptoms
suggestive of IBS may actually turn out to have CD [21].
In our study, 64% of the subjects had a previous diagno-
sis of IBS. Characteristically, these patients were older
(p = 0.004), had more consultations (p = 0.05), and had
a long history of symptoms (p = 0.06). Similar findings
have been reported by other authors. In a large, biopsy-
confirmed study that was carried out by means of a postal
survey (n = 225), Barrat et al. found that 44% of the CD
subjects had a previous IBS diagnosis [22]. A more recent
study reported that 16% of individuals with CD had this
same prior diagnosis, compared with 4.9% of controls;
many of the IBS diagnoses were made within the year be-
fore CD diagnosis, but there was a clear excess of IBS
diagnoses as much as 10 years earlier [23]. According to
our results, an excess of prior IBS diagnoses is related to a
diagnostic delay for CDin Mexico; this has also been re-
ported in the UK and other countries. Therefore, health-
care providers should now be aware of this situation.
IBS is not the only functional gastrointestinal disorder
that may serve as a reservoir for CD patients. The symp-
toms of CD can also overlap with those of functional
dyspepsia. CD prevalence in dyspepsia has been reported
at 1.2-6.2% and may be higher if the entire spectrum of
lesions related to gluten sensitivity is taken into account
[24]. In our study, 23 (28.8%) of the patients had been
diagnosed with functional dyspepsia 3.6 years before being
diagnosed with CD.
In regard to QoL determination through the EQ-5D,
we found that Mexican CD patients had a poor QoLuroQoL VAS, post-diagnosis) and anxiety and depression
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QoL improves once patients are aware of the diagnosis
and as soon as they start a GFD [1,25]. For example, one
study in the UK concluded that the health-related QoL
before CD diagnosis was quantitatively similar to that of
stroke patients, and it improved after treatment with a
GFD was begun, with scores as good as those of the gen-
eral population [7]. In our study, there was a significant
increase after diagnosis in the percentage of patients that
reported having no problems in any of the 5 domains of
the EQ-D5. Furthermore, there was a statistically signifi-
cant increase after diagnosis in the mean value of the
pre-diagnosis QoL using the visual scale of the EQ-D5
(from 50 to 76 points). Our results are similar to those
reported by Norström et al. in a Swedish cohort of 1,031
CD patients, in which the mean QoL score during the
year prior to treatment initiation was low (66 points)
and it improved after diagnosis and treatment, reaching
86 points (an increase of 20 points) [3].
In relation to the CSI, 20 of our patients (39.2%) had a
score > 45, which has been associated with poor Qol [12].
Previous studies report that women with treated CD ex-
perience worse QoL than men. However, in our study, sex
was not associated with poor QoL. As has been previously
reported [26,27], we found that the delay in CD diagnosis
was markedly associated with worse QoL. Another im-
portant predictor of reduced QoL was the high prevalence
of IBS and dyspepsia symptoms among patients with CD
[28,29]. The presence of functional gastrointestinal symp-
toms in patients with CD is associated with reduced QoL,
making those patients more likely to present with anxiety
and depression, or vice versa [27,28].
Negative psychological disorders such as anxiety and
depression have also been found to be associated with
reduced QoL among patients with CD [30]. In a recent
meta-analysis, 18 studies on depression and 11 studies
on anxiety in adult CD subjects reliably showed that
depression was more common and/or more severe in
adults with CD than in healthy adults (overall meta-
analysis effect size: 0.97) [31]. In a study by Häuser
et al. [28], 441 patients with CD and 441 subjects from
the general population were assessed by the HADS.
The prevalence of anxiety disorder found in the persons
with CD (16.8%) was higher than that of the general
population (5.7%) (p < 0.001). In our study, according to
the HADS, 65% of the CD patients presented with anx-
iety and 60% with depression at the time of the analysis,
and there was a negative correlation with QoL using
the EQ-D5 VAS.
Currently, the only treatment for celiac disease is a
strict life-long GFD, and despite the fact that this
approach has been shown to be beneficial, the diet is
troublesome, sometimes expensive, and socially res-
trictive [25,26]. These negative effects, together with alate diagnosis of the disease, have a negative influence
on the QoL of individuals with CD [25]. In relation to
our study, we believe that although the QoL score in
our patients increased after diagnosis (using the EQ-5D),
the prevalence of anxiety and depression remained higher,
partially due to the social and cultural issues involved.
In addition, the lack of information motivating ad-
herence to a GFD may play a role in a country such as
Mexico.
Even though our study presents novel and relevant data
on Mexican Mestizo patients with CD, we recognize its
limitations. In the past, CD was regarded as an infrequent
disease in the Mexican population, and most of the cases
were diagnosed at a tertiary referral center such as ours.
This could result in selection bias due to the fact that
those persons with more severe disease sought medical at-
tention. However, CD awareness is increasing in Mexico
and we are now seeing patients with a wider spectrum of
CD manifestations, ranging from patients presenting with
classic GI symptoms to those with extraintestinal manifes-
tations, such as infertility.
Questionnaires are limiting in general, as there may be
bias, particularly when addressing specific aspects. For
example, in our study, QoL before and after diagnosis is
conducive to recall bias, and the correlation between
anxiety, depression, and QoL, before and after diagnosis,
could be affected by such bias.Conclusions
Nevertheless, our study is the first formal characteri-
zation of Mexican CD patients and it showed that long-
standing undiagnosed CD and the previous diagnosis of
functional disorders were associated with worse QoL in
the study population. Our results support the need for a
detailed examination of cost-effective strategies for in-
creasing awareness about under-diagnosed CD in clinical
practice in Mexico.
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